Healthcare > Pharmaceuticals & Biotechnology
•2432 stocks
•
Total Market Cap: Loading...
Price Performance Heatmap
5Y Price (Market Cap Weighted)
All Stocks (2432)
| Company | Market Cap | Price |
|---|---|---|
|
FOLD
Amicus Therapeutics, Inc.
Galafold is an oral pharmacological chaperone and Pombiliti + Opfolda include an oral stabilizer; both are delivered as oral small molecule drugs, making Oral Small Molecule Therapeutics a core product category.
|
$4.42B |
$14.32
+0.07%
|
|
ACAD
ACADIA Pharmaceuticals Inc.
ACADIA's portfolio includes Pimavanserin (NUPLAZID) and pipeline candidates that are small-molecule therapeutics, with additional small-molecule programs (e.g., ACP-204, ACP-711).
|
$4.38B |
$25.98
-2.05%
|
|
AKRO
Akero Therapeutics, Inc.
EFX is a biologic drug with a specialized delivery formulation (pre-filled syringe/lyophilized product), placing it squarely in the Drug Delivery Platforms category.
|
$4.37B |
$54.67
+0.04%
|
|
LNTH
Lantheus Holdings, Inc.
Directly produces radiopharmaceutical imaging agents and related therapies (e.g., PYLARIFY, DEFINITY) and maintains an expanding pipeline in this modality.
|
$4.37B |
$64.22
-1.83%
|
|
SRRK
Scholar Rock Holding Corporation
Directly develops and markets monoclonal antibody therapeutics (apitegromab, SRK-439, SRK-181) across SMA, obesity/metabolic, and oncology.
|
$4.32B |
$44.98
-3.33%
|
|
AMRX
Amneal Pharmaceuticals, Inc.
Main revenue driver is generic drugs in Affordable Medicines.
|
$4.21B |
$13.40
+1.63%
|
|
CGON
CG Oncology, Inc. Common stock
CG Oncology is a biotech company focused on oncology therapies, with cretostimogene grenadenorepvec representing an oncology product in late-stage development.
|
$4.17B |
$54.66
+3.00%
|
|
ADMA
ADMA Biologics, Inc.
ADMA's core offerings are plasma-derived immunology therapeutics (immunoglobulins) used to treat immune deficiencies and related conditions.
|
$4.13B |
$17.32
-1.06%
|
|
LEGN
Legend Biotech Corporation
CARVYKTI is a CAR-T cell therapy and Legend Biotech's flagship product, representing its direct cell-therapy manufacturing and commercialization activity.
|
$4.09B |
$22.14
+0.11%
|
|
INDV
Indivior PLC
SUBLOCADE's extended-release delivery represents a drug delivery platform (monthly dosing), a core investable theme.
|
$4.06B |
$32.53
-1.06%
|
|
ACLX
Arcellx, Inc.
Company's lead products are CAR-T cell therapies within oncology; direct product category is cell therapy.
|
$3.82B |
$68.96
+0.94%
|
|
VKTX
Viking Therapeutics, Inc.
VK2735 is a peptide-based dual GLP-1/GIP receptor agonist, the company's lead therapeutic.
|
$3.81B |
$33.93
+6.43%
|
|
LGND
Ligand Pharmaceuticals Incorporated
Captisol and NITRICIL are platform technologies Ligand licenses/sells to enable drug solubility and tunable dosing, constituting drug delivery platforms.
|
$3.78B |
$193.12
-1.51%
|
|
CORT
Corcept Therapeutics Incorporated
Corcept develops and commercializes oral small-molecule cortisol modulators (Korlym, relacorilant) for hypercortisolism and oncology, fitting 'Oral Small Molecule Therapeutics'.
|
$3.66B |
$34.76
-1.78%
|
|
NAMS
NewAmsterdam Pharma Company N.V.
Lead asset obicetrapib is an oral, small-molecule therapeutic, aligning with the 'Oral Small Molecule Therapeutics' category.
|
$3.56B |
$31.68
-0.47%
|
|
SWTX
SpringWorks Therapeutics, Inc.
SpringWorks specializes in oncology therapies using targeted small-molecule modalities (nirogacestat and mirdametinib).
|
$3.52B |
$46.99
|
|
VCYT
Veracyte, Inc.
Tests function as companion diagnostics to identify patients most likely to benefit from specific therapies.
|
$3.27B |
$41.61
+1.49%
|
|
LQDA
Liquidia Corporation
Liquidia's YUTREPIA is a PRINT-enabled inhaled treprostinil, a drug-delivery platform that enables high-dose, deep-lung delivery and differentiated pharmacokinetics.
|
$3.27B |
$37.90
-2.29%
|
|
PBH
Prestige Consumer Healthcare Inc.
Fleet and other PBH brands address digestive health with OTC solutions.
|
$3.20B |
$65.12
-0.75%
|
|
TERN
Terns Pharmaceuticals, Inc.
The company is advancing oral small-molecule therapeutics (TERN-701 and TERN-601) for cancer and obesity, aligning with the 'Oral Small Molecule Therapeutics' investable theme.
|
$3.20B |
$36.63
-0.95%
|
|
BEAM
Beam Therapeutics Inc.
Beam's core offering is a base editing gene therapy platform (DNA editing to correct disease-causing mutations).
|
$3.16B |
$31.29
-2.39%
|
|
IDYA
IDEAYA Biosciences, Inc.
IDEAYA is a biotechnology company focused on precision oncology therapies (synthetic lethality and ADCs).
|
$3.14B |
$35.83
-0.64%
|
|
WGS
GeneDx Holdings Corp.
Companion diagnostics partnerships leverage genomic data to identify patients for therapies.
|
$3.10B |
$107.89
-1.27%
|
|
ARQT
Arcutis Biotherapeutics, Inc.
Arcutis' ZORYVE topical PDE4 inhibitor targets inflammatory dermatologic conditions, aligning with Immunology Therapeutics.
|
$3.10B |
$25.86
-1.92%
|
|
XENE
Xenon Pharmaceuticals Inc.
Xenon's lead asset XEN1101 is a selective Kv7 potassium channel opener, mapping to Ion Channel Modulators.
|
$3.08B |
$40.02
-1.77%
|
|
ITGR
Integer Holdings Corporation
Integer is a contract development and manufacturing organization (CDMO) for medical devices, directly providing design, development and manufacturing services to OEMs.
|
$3.01B |
$85.77
+0.57%
|
|
TARS
Tarsus Pharmaceuticals, Inc.
XDEMVY is an FDA-approved ophthalmic drug and core commercial product for Demodex blepharitis.
|
$3.00B |
$71.15
-3.39%
|
|
CNTA
Centessa Pharmaceuticals plc
ORX750 is an orally administered, high-potency orexin receptor 2 (OX2R) agonist, fitting the 'Oral Small Molecule Therapeutics' category.
|
$2.98B |
$22.14
-1.18%
|
|
VERA
Vera Therapeutics, Inc.
Atacicept is a biologic therapeutic (dual BAFF/APRIL inhibitor) with a monoclonal antibody–like profile, placing Vera's lead program under Monoclonal Antibody Therapeutics.
|
$2.97B |
$46.55
+0.59%
|
|
KNSA
Kiniksa Pharmaceuticals, Ltd.
Kiniksa's core clinical focus centers on immunology therapeutics, driven by ARCALYST and its inflammatory disease pipeline.
|
$2.92B |
$39.42
+3.96%
|
|
EWTX
Edgewise Therapeutics, Inc.
Edgewise's lead programs sevasemten and EDG-7500 are orally administered small-molecule therapeutics, i.e., an oral small molecule therapeutics platform.
|
$2.89B |
$27.41
+3.06%
|
|
SUPN
Supernus Pharmaceuticals, Inc.
Supernus is focused on CNS/neuropsychiatric drug development with a pipeline spanning ADHD, depression, epilepsy, and Parkinson's disease, including SPN-817, SPN-820, and SPN-443.
|
$2.80B |
$50.04
-0.44%
|
|
CPRX
Catalyst Pharmaceuticals, Inc.
The company focuses on rare diseases with its portfolio of therapies addressing small patient populations.
|
$2.78B |
$22.71
-1.09%
|
Showing page 5 of 25 (2432 total stocks)
Loading company comparison...
Loading industry trends...
Loading research report...
